Evidence map›Paper›PMID 31666564›Full record

ArticleScientific reports2019

Characterisation of proguanylin expressing cells in the intestine - evidence for constitutive luminal secretion.

Florent Serge Dye, Pierre Larraufie, Richard Kay, Tamana Darwish, Juraj Rievaj, Deborah A Goldspink, Claire L Meek, Stephen J Middleton, Richard H Hardwick, Geoffrey P Roberts and 8 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. The Natriuretic Peptide System: A Single Entity, Pleiotropic Effects.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Florent Serge DyeWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Pierre LarraufieWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Richard KayWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Tamana DarwishWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Juraj RievajWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Deborah A GoldspinkWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Claire L MeekWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Stephen J MiddletonDepartment of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Richard H HardwickBarrett's Oesophagus and Oesophago-gastric Cancer, Gastroenterology Services, Addenbrooke's Hospital, Cambridge, UK.
Geoffrey P RobertsWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Jennifer L Percival-AlwynDepartment of Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge, UK.
Tris VaughanDepartment of Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge, UK.
Franco FerraroDepartment of Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge, UK.
Benjamin G ChallisResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Stephen O'RahillyWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-2199-4449
Maria GrovesDepartment of Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge, UK. grovesm@medimmune.com.
Fiona M GribbleWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Frank ReimannWellcome/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. fr222@cam.ac.uk.ORCID http://orcid.org/0000-0001-9399-6377
University of Cambridge · GBAstraZeneca (United Kingdom) · GBAddenbrooke's Hospital · GBCambridge University Hospitals NHS Foundation Trust · GB

Funding

Medical Research Council MC_UU_00014/1Medical Research Council MC_UU_00014/3Medical Research Council MC_UU_00014/5Medical Research Council MC_UU_12012/1Medical Research Council MC_UU_12012/3Medical Research Council MC_UU_12012/5Medical Research Council MR/M009041/1Medical Research Council MR/M024873/1RCUK | Medical Research Council (MRC) MRC_MC_UU_12012/3RCUK | MRC | Medical Research Foundation MR/M009041/1Wellcome TrustWellcome Trust (Wellcome) 100574/Z/12/ZWellcome Trust (Wellcome) 106262/Z/14/ZWellcome Trust (Wellcome) 106263/Z/14/Z
6 · The paper itself

Abstract

Guanylin, a peptide implicated in regulation of intestinal fluid secretion, is expressed in the mucosa, but the exact cellular origin remains controversial. In a new transgenic mouse model fluorescent reporter protein expression driven by the proguanylin promoter was observed throughout the small intestine and colon in goblet and Paneth(-like) cells and, except in duodenum, in mature enterocytes. In Ussing chamber experiments employing both human and mouse intestinal tissue, proguanylin was released predominantly in the luminal direction. Measurements of proguanylin expression and secretion in cell lines and organoids indicated that secretion is largely constitutive and requires ER to Golgi transport but was not acutely regulated by salt or other stimuli. Using a newly-developed proguanylin assay, we found plasma levels to be raised in humans after total gastrectomy or intestinal transplantation, but largely unresponsive to nutrient ingestion. By LC-MS/MS we identified processed forms in tissue and luminal extracts, but in plasma we only detected full-length proguanylin. Our transgenic approach provides information about the cellular origins of proguanylin, complementing previous immunohistochemical and in-situ hybridisation results. The identification of processed forms of proguanylin in the intestinal lumen but not in plasma supports the notion that the primary site of action is the gut itself.

Indexed as

Gene Expression RegulationGastrointestinal HormonesHumansIntestinal MucosaNatriuretic PeptidesProtein PrecursorsGastrointestinal HormonesguanylinNatriuretic PeptidespreproguanylinProtein Precursors

Identifiers

PMID31666564
PMCPMC6821700
OpenAlexW2982575994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.